Peter D. Flynn

Ren Pharmaceuticals was formed in the fall of 2006 with the aim of bringing together talented and experienced people who are passionate about building a cardio-renal/renal- focused drug development company. Ren Pharmaceuticals closed a Series A financing in November 2006 with Sanderling Ventures, Venrock Associates and Amgen Ventures as investors. The company's R&D is currently located in South San Francisco, California.

UCSF Medical Center owns and operates hospitals. It operates hospitals in San Francisco as well as satellite facilities. It provides health care facilities to children, organ transplants, cardiac care, fertility treatments, neurosurgery, ophthalmology, and orthopedics. It also provides outpatient care and some programs in areas as women's health, aging, cancer, and pain management. UCSF Medical Center is headquartered in San Francisco, CA.

Orexigen Therapeutics, Inc. is a biopharmaceutical company, which focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its primary activities include recruiting personnel, conducting research and development, including clinical trials, raising capital, and preparing for the marketing and commercialization of its product, contrave. The company was founded by Eckard Weber in September 2002 and is headquartered in La Jolla, CA.